Health TrialsbyHealthPanel

Decreasing Nightmares in Adults With Narcolepsy

ConditionsNarcolepsyNarcolepsy Type 1Narcolepsy With CataplexyNarcolepsy Without CataplexyNightmareNightmare Disorder With Associated Other Sleep Disorder
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Utah

About this trial

The purpose of this clinical trial is learn whether a behavioral (non-medication) treatment can reduce nightmares in adults with narcolepsy. All participants will receive the treatment and will complete three assessments. Half of the participants will receive the treatment after the first assessment, and half will receive it after the second assessment. Romantic partners of participants with narcolepsy will also be eligible to enroll in the study. Partners will complete three assessments but will not participate in the treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Diagnosis of narcolepsy type 1 or narcolepsy type 2

Nightmare frequency of ≥1 times per week

Age 18 or older

Able to speak, read, and write in English

Disqualifiers

Currently engaged in trauma- or sleep-related psychotherapy

Previous behavioral treatment for nightmares

Medical, psychiatric, or cognitive condition which would interfere with ability to engage in the treatment

Untreated moderate-severe sleep apnea

Trial design

Design model

Crossover

Treatments tested in this trial

  • Imagery Rehearsal Therapy (IRT)

    Behavioral

    The intervention will consist of 7 therapy sessions (once per week for 7 weeks) which will be delivered via videoconference. During the sessions, participants will learn techniques for managing and changing nightmares.

Treatment groups

80 Participants
are divided into 2 treatment groups
Group A: TreatmentExperimental treatment 1 intervention
Group B: WaitlistOther 1 intervention

Trial outcomes

Primary outcomes

1

Disturbing Dream and Nightmare Severity Index (DDNSI)

The DDNSI is a questionnaire which measures the severity of nightmares.

Time frame
Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)
2

Nightmare frequency (sleep diary)

The number of nightmares experienced each day will be collected on daily sleep diaries completed during each assessment period.

Time frame
Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)

Secondary outcomes

1

PROMIS Anxiety

Questionnaire which measures the severity of anxiety symptoms.

Time frame
Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)
2

PROMIS Depression

Questionnaire which measures the severity of depressive symptoms.

Time frame
Completed at each of the three assessments (baseline, 10 weeks, 19 weeks)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University of Utah

Lead sponsor

Source ClinicalTrials.gov
Apply now